Axsome Therapeutics, Inc. (AXSM)
| Market Cap | 10.95B +112.5% |
| Revenue (ttm) | 708.24M +63.9% |
| Net Income | -188.30M |
| EPS | -3.74 |
| Shares Out | 51.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,023,411 |
| Open | 210.13 |
| Previous Close | 210.13 |
| Day's Range | 208.61 - 214.39 |
| 52-Week Range | 101.88 - 260.19 |
| Beta | 0.73 |
| Analysts | Strong Buy |
| Price Target | 282.32 (+32.71%) |
| Earnings Date | Aug 10, 2026 |
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]
Financial Performance
In 2025, Axsome Therapeutics's revenue was $638.50 million, an increase of 65.55% compared to the previous year's $385.69 million. Losses were -$183.17 million, -36.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price target is $282.32, which is an increase of 32.71% from the latest price.
News
Axsome Therapeutics price target lowered to $306 from $310 at Mizuho
Mizuho lowered the firm’s price target on Axsome Therapeutics (AXSM) to $306 from $310 and keeps an Outperform rating on the shares.
Axsome Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Malcolm Hoffman initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price target The firm says the recent approval of Axsome’s Auvelity in Agitation...
Axsome Therapeutics initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price target
Axsome Therapeutics announces FDA acceptance of AXS-12 NDA
Axsome Therapeutics (AXSM) announced that the FDA has accepted for filing the company’s new drug application for AXS-12 for the treatment of cataplexy in narcolepsy. The FDA has set a…
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of...
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics price target raised to $304 from $302 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Axsome Therapeutics (AXSM) to $304 from $302 and keeps an Outperform rating on the shares as part of a…
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm...
Why Axsome Stock Has Doubled In Nine Months
In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more. To get it in your inb...
Axsome Therapeutics doses first patient in FOCUS-3 trial
Axsome Therapeutics (AXSM) announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity diso...
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics price target raised to $300 from $275 at TD Cowen
TD Cowen analyst Joseph Thome raised the firm’s price target on Axsome Therapeutics (AXSM) to $300 from $275 and keeps a Buy rating on the shares. The firm said management…
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The session highlighted a strong CNS focus, rapid organizational growth, and a robust pipeline. AUVELITY's recent ADA approval and label advantages drove a peak sales guidance increase to $8 billion, supported by expanded sales force and payer coverage. Commercial and marketing strategies leverage synergies across indications.
Axsome Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Three commercial CNS products drive growth, with Auvelity's Alzheimer's agitation launch imminent and peak sales guidance raised to $8B. Pipeline advances include new phase III studies for smoking cessation and binge eating, while expanded sales force and improved market access are expected to boost revenue in the second half of the year.
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics Transcript: 46th Annual William Blair Growth Stock Conference
AUVELITY received new approval for Alzheimer's agitation, driving expanded growth and a raised peak sales forecast. Commercial and pipeline assets are expected to exceed $18 billion in peak sales, with strong financials and a broad CNS pipeline supporting future profitability.
Axsome Therapeutics announces settlement resolving Sunosi patent litigation
Axsome Therapeutics (AXSM) announced that it has resolved all patent litigation related to Axsome’s product Sunosi. The litigations resulted from submission of abbreviated new drug applications to the...
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,...
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today hi...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...
Axsome Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
FDA approval for a new Alzheimer's agitation treatment with a differentiated safety and efficacy profile is driving a June launch, supported by a major sales force expansion and strong payer access. Growth continues in MDD, migraine, and sleep markets, with a robust pipeline in CNS disorders.
Axsome Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
AUVELITY's new ADA indication and strong MDD performance are driving a major sales force expansion and broader market access, with robust payer coverage and minimal patient out-of-pocket costs. Growth targets remain ambitious, supported by disciplined DTC investment and a promising pipeline including SYMBRAVO and SUNOSI.